Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 ,inter alia, to consider and approve Unaudited Standalone and ....
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jubilant Pharmova Ltd has informed the stock exchanges that its Board of Directors will meet on Friday, February 6, 2026. The Board will consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025 (i.e., Q3 FY26 results). The filing is a standard regulatory disclosure under SEBI Listing Regulations and contains no actual financial figures. The approved results will also be uploaded to the company's website.
This is a routine advance notice ahead of the Q3 FY26 earnings announcement. Investors should watch for the actual results on or after February 6, 2026, as the numbers could move the stock. No immediate price impact is expected from this intimation itself.